Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01898130 · ClinicalTrials.gov registry record · Phase 2
Bevacizumab in Pats w/ Recurrent ST Brain Metas Who Have Failed Whole Brain Radiation Therapy
A Phase 2 study of Metastatic Cancer and Unspecified Adult Solid Tumor, Protocol Specific, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
- 4
- Study locations
NCT01898130 is a Phase 2 study of Metastatic Cancer and Unspecified Adult Solid Tumor, Protocol Specific that has completed, run by Northwestern University. The registered enrollment target is 27 participants, below the 444-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (94% lower). The trial reports 4 study locations across 2 states.
The verdict
NCT01898130, a Phase 2 study of Metastatic Cancer and Unspecified Adult Solid Tumor, Protocol Specific, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a study to evaluate a drug called bevacizumab in patients with cancer whose disease has spread to their brain. This study will not evaluate the effect of bevacizumab on the systemic solid tumor cancer. Bevacizumab is a medication and it is thought that bevacizumab may interfere with the growth of new blood vessels; therefore it might stop tumor growth and possibly shrink the tumor by keeping it from receiving nutrients and oxygen supplied by the blood vessels.
Conditions Studied
Interventions
- PROCEDURE quality-of-life assessment
- BIOLOGICAL bevacizumab
Study Locations (4)
Illinois
- Northwestern University - Chicago
- Northwestern Memorial Hospital: Lake Forest Hospital - Lake Forest
- Cadence Health - CDH - Warrenville
New York
- Columbia University Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2013-11-27 |
| Est. Completion | 2018-09-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01898130
The ClinicalTrials.gov registry entry for NCT01898130 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 444-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (94% lower). The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Metastatic Cancer appearing as the primary indexed condition, and to 2 interventions - of which quality-of-life assessment is the first listed.
NCT01898130 reports 4 study locations spanning 2 distinct geographic areas - top geographies include Illinois, New York.
Frequently Asked Questions
What is clinical trial NCT01898130 about?
NCT01898130 is a clinical study titled "Bevacizumab in Pats w/ Recurrent ST Brain Metas Who Have Failed Whole Brain Radiation Therapy". This is a study to evaluate a drug called bevacizumab in patients with cancer whose disease has spread to their brain. This study will not evaluate the effect of bevacizumab on the systemic solid tumor cancer. Bevacizumab is a medication and it is thought that bevacizumab may interfere with the grow...
What is the current status of trial NCT01898130?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2013-11-27. Estimated completion is 2018-09-05.
What conditions does trial NCT01898130 study?
This clinical trial studies the following conditions: Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific.
What interventions are being tested in trial NCT01898130?
The interventions under investigation include: quality-of-life assessment (PROCEDURE), bevacizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01898130?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01898130 being conducted?
This trial has 4 study locations across Illinois, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change
RECRUITING · Phase 2
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
RECRUITING · Phase 2
-
Biomarkers to Detect Endocrine Therapy Resistance
RECRUITING · Phase 2
-
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
RECRUITING · Phase 2
-
Definitive Radiation for High-Risk Spine Metastases
RECRUITING · Phase 2
Explore more on PlainTrial
Metastatic Cancer
All registered trials for this condition
Unspecified Adult Solid Tumor, Protocol Specific
All registered trials for this condition
Illinois
All trials with a study site in Illinois
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.